SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 


No3(4) 2021

Back to the issue


DOI 10.37219/2528-8253-2021-3-82

Kosakovskyi A.
Evaluation of efficiency and safety of apicold mint nose spray for allergic rhinitis
Kosakovsky Anatoly L.
Shupyk National Healthcare University of Ukraine
Head of Department of Pediatric Otorhinolaryngology, Audiology, Phoniatrics
Doctor of Medical Sciences, Professor
E-mail: akosakovskyi@gmail.com
ORCID ID: 0000-0001-7194-420X

Abstract

Introduction: Allergic rhinitis affects 10 to 40% of the population, and among children the incidence is 2-25%.
Aim: Evaluation of the effectiveness and safety of "Apicold Mint" nasal spray in children and adults with allergic rhinitis.
Material and methods: The effect of "Apicold Mint" Nasal Spray (manufactured by APIPHARMA doo) was studied in 45 patients with allergic rhinitis. The clinical study involved 21 (47%) children aged 4 to 18 years and 24 (53%) adults.
Results and discussion: The use of the drug "Apicold Mint" nasal spray helps to reduce the symptoms of allergic rhinitis and eliminates the feeling of dryness, which often occurs with the use of topical corticosteroids and decongestants. In addition, the use of the drug "Apicold Mint" nasal spray significantly reduced the need for vasoconstrictor drops, which is also positive in the treatment of patients with allergic rhinitis.
Conclusion: Appointment of the drug "Apicold Mint" nasal spray in the complex therapy of allergic rhinitis contributes to a faster reduction of symptoms and increases the effectiveness of local drugs.

Keywords

"Apicold mint" nasal spray, menthol, globules of eucalyptus oil, allergic rhinitis, children, adults.


Reference

  1. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-334. doi: 10.1067/mai.2001.118891.
  2. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multcountry cross-sectional surveys. Lancet. 2006;368 (9537):733-43. doi: 10.1016/S0140-6736(06)69283-0.
  3. Zabolotko VM, Kosakovskiy AL, Rudenko NG, Rudenko OV. Otolaryngological care for children 0-17 years old inclusive, under supervision in health care institutions in the sphere of management of the Ministry of Health of Ukraine for 2016. Center for Health Statistics, Ministry of health of Ukraine, 2017. 156 с.
  4. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050.
  5. Yurochko F, Kosakovsky A, Shkorbotun V, ed. [Pediatric rhinology]. Study guide. Lviv: MC, 2020. 288 p. [In Ukrainian].
  6. https://apipharma.hr/hr/o-nama
  7. https://compendium.com.ua/dec/340349/
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»